[go: up one dir, main page]

AR061058A1 - Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas - Google Patents

Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas

Info

Publication number
AR061058A1
AR061058A1 ARP070102193A ARP070102193A AR061058A1 AR 061058 A1 AR061058 A1 AR 061058A1 AR P070102193 A ARP070102193 A AR P070102193A AR P070102193 A ARP070102193 A AR P070102193A AR 061058 A1 AR061058 A1 AR 061058A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
fluor
alkoxy
cycloalkyl
alkyl
Prior art date
Application number
ARP070102193A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR061058A1 publication Critical patent/AR061058A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)

Abstract

Estos compuestos son agonistas de HM74A y pueden utilizarse como medicamentos. Procesos de obtencion de los mismos y composiciones farmacéuticas. Reivindicacion 1: Compuestos de la formula (1) en la que X es un enlace sencillo, O, N(R9)C(O), N(R9)C(O)O, OC(O)NR9, N(R9)C(O)NR10 o N(R9)SO2, o, si m es 1, 2 o 3, X puede ser también C(O)NR9; Y es un enlace sencillo, o, si n es 1, 2, 3, 4, 5 o 6, Y puede ser también O; R1, R2 y R3 con independencia entre sí son hidrogeno, halogeno, alquilo inferior, fluor-alquilo inferior, alcoxi inferior, fluor-alcoxi inferior o cicloalquilo; R4, R5, R6 y R7 con independencia entre sí son hidrogeno, fluor, alquilo inferior o fluor-alquilo inferior, o R4 y R5 junto con el átomo de carbono al que están unidos forman un anillo y -R4-R5- es -(CH2)2-6-, o R6 y R7 junto con el átomo de carbono al que están unidos forman un anillo y -R6-R7- es -(CH2)2-6; R8 es arilo o heteroarilo, dicho arilo o heteroarilo está opcionalmente sustituido con 1 a 3 sustituyentes seleccionados del grupo formado por halogeno, alquilo inferior, alcoxi inferior, fluor-alquilo inferior, fluor-alcoxi interior, cicloalquilo, fluor-cicloalquilo, cicloalquil-oxi, C(O)OH, alcoxi inferior-C(O), NH2C(O), N(H,alquilo inferior)C(O), N(alquilo inferior)2C(O), OH, alquilo inferior-C(O)O, NH2, N(H,alquilo inferior), N(alquilo inferior)2, alquilo inferior-C(O)NH, alquilo inferior-C(O)N(alquilo inferior), NH2SO2, N(H,alquilo inferior)SO2, N(alquilo inferior)2SO2, alquilo inferior-SO2-NH, alquilo interior-SO2-N(alquilo inferior), ciano y fenilo, que está opcionalmente sustituido con 1 a 3 sustituyentes seleccionados del grupo formado por halogeno, alquilo inferior, alcoxi inferior y fluor-alquilo inferior; R9 y R10 con independencia entre sí son hidrogeno, alquilo inferior o fluoralquilo inferior; m es 0,1, 2 o 3; n es 0,1, 2, 3, 4, 5 o 6; en la que m + n es >= 1; y las sales y ésteres farmacéuticamente aceptables de los mismos.
ARP070102193A 2006-05-23 2007-05-21 Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas AR061058A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06114438 2006-05-23

Publications (1)

Publication Number Publication Date
AR061058A1 true AR061058A1 (es) 2008-07-30

Family

ID=38537108

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102193A AR061058A1 (es) 2006-05-23 2007-05-21 Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas

Country Status (17)

Country Link
US (1) US7572801B2 (es)
EP (1) EP2029601B1 (es)
JP (1) JP5112423B2 (es)
KR (1) KR101083490B1 (es)
CN (1) CN101448836B (es)
AR (1) AR061058A1 (es)
AT (1) ATE469905T1 (es)
AU (1) AU2007253513B2 (es)
BR (1) BRPI0711879A2 (es)
CA (1) CA2651573C (es)
CL (1) CL2007001452A1 (es)
DE (1) DE602007006947D1 (es)
ES (1) ES2344086T3 (es)
IL (1) IL195013A0 (es)
MX (1) MX2008014689A (es)
TW (1) TW200804369A (es)
WO (1) WO2007134986A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008231873B2 (en) * 2007-03-23 2011-11-10 F. Hoffmann-La Roche Ag Aza-pyridopyrimidinone derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2011503193A (ja) * 2007-11-13 2011-01-27 アイコス、コーポレーション ヒトホスファチジルイノシトール３−キナーゼδの阻害剤
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
JP5606444B2 (ja) * 2008-11-07 2014-10-15 フイルメニツヒ ソシエテ アノニム フローラルおよび／またはアニスタイプの芳香成分
EP2379547A1 (en) * 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
TWI475051B (zh) 2009-11-18 2015-03-01 Kao Corp Organic polysiloxane
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
CN102321015A (zh) * 2011-06-30 2012-01-18 江苏德峰药业有限公司 一种抗艾滋病药物奈韦拉平关键中间体 2-(环丙胺基）-3-甲酸吡啶的制备方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2015025326A1 (en) * 2013-08-19 2015-02-26 Council Of Scientific & Industrial Research 3-(4-ethynylphenyl) pyridopyrimidinone compounds and process for preparation thereof useful as potential antic ancer agents
CN103694255A (zh) * 2014-01-09 2014-04-02 华中师范大学 吡啶并噁嗪酮和吡啶并嘧啶酮类化合物及其制备方法与应用
CN103819414B (zh) * 2014-02-27 2016-06-01 福建医科大学 一种在水相中催化制备喹唑酮化合物的方法
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
JP6661606B2 (ja) * 2014-09-12 2020-03-11 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． 新規ピリドピリミジン誘導体化合物
WO2018148733A1 (en) * 2017-02-13 2018-08-16 Neuralstem, Inc. Amelioration of certain deficiencies due to stroke
CN108218861B (zh) * 2018-02-05 2019-07-23 黑龙江中医药大学 一种预防和治疗糖尿病的药物及其制备方法
MX2021014116A (es) * 2019-05-31 2021-12-10 Chiesi Farm Spa Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
CA3195519A1 (en) 2020-09-18 2022-03-24 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
EP4587439A1 (en) 2022-09-16 2025-07-23 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
WO2024079252A1 (en) 2022-10-13 2024-04-18 Bayer Aktiengesellschaft Sos1 inhibitors
WO2025202022A1 (en) 2024-03-27 2025-10-02 Bayer Aktiengesellschaft Anticancer macrocyclic quinazoline-based inhibitors of the ineraction between ras and sos1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2038035A1 (de) * 1970-07-31 1972-02-03 Boehringer Mannheim GmbH, 6800 Mannheim-Waldhof 2-Amino-pyrido eckige Klammer auf 2,3-d eckige Klammer zu pyrimidin-4(3H)on-Derivate
US3950160A (en) * 1972-09-27 1976-04-13 Pfizer Inc. Inhibiting the growth of weeds with 2-substituted pyrdidopyimidines and salts thereof
US3862191A (en) * 1972-09-27 1975-01-21 Pfizer Pyrido{8 2,3-d{9 pyrimidin-4(3H)-one
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
WO2005077950A2 (en) * 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
JP2005250037A (ja) * 2004-03-03 2005-09-15 Fuji Photo Film Co Ltd ヒートモード対応ポジ型画像記録材料
MXPA06012333A (es) * 2004-04-30 2007-01-17 Takeda Pharmaceutical Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13.
JP2006184517A (ja) * 2004-12-27 2006-07-13 Fuji Photo Film Co Ltd ヒートモード対応ポジ型画像記録材料

Also Published As

Publication number Publication date
WO2007134986A1 (en) 2007-11-29
MX2008014689A (es) 2008-11-27
EP2029601A1 (en) 2009-03-04
CL2007001452A1 (es) 2008-01-04
US20070275987A1 (en) 2007-11-29
KR101083490B1 (ko) 2011-11-16
ES2344086T3 (es) 2010-08-17
CN101448836A (zh) 2009-06-03
AU2007253513A1 (en) 2007-11-29
BRPI0711879A2 (pt) 2012-01-10
TW200804369A (en) 2008-01-16
ATE469905T1 (de) 2010-06-15
CA2651573A1 (en) 2007-11-29
JP5112423B2 (ja) 2013-01-09
CN101448836B (zh) 2011-12-14
AU2007253513B2 (en) 2010-07-08
CA2651573C (en) 2011-12-06
DE602007006947D1 (de) 2010-07-15
EP2029601B1 (en) 2010-06-02
US7572801B2 (en) 2009-08-11
JP2009537588A (ja) 2009-10-29
KR20090008390A (ko) 2009-01-21
IL195013A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR077440A1 (es) Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
UY29703A1 (es) "inhibidores macrocíclicos del virus de la hepatitis c"
PE20130155A1 (es) Derivados de ariletinilo
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
AR033295A1 (es) Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR061847A1 (es) Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas.
PE20130229A1 (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR058124A1 (es) Derivados de ftalazinona como inhibidores de parp-1
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
PE20140968A1 (es) Derivados de benzamida sustituida
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR065587A1 (es) Aminoamidas como antagonistas de orexina
AR069814A1 (es) Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen
AR073565A1 (es) Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen
CO6241117A2 (es) Derivados de n-(fenil) -n-morfolin-4-il-piridin -2-il) - -pirimidina-2, 4-diamina como inhibidores del ephb4 quinasa para el tratamiento de condiciones proliferativas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal